Determination of ziprasidone in human plasma by liquid chromatography-electrospray tandem mass spectrometry and its application to plasma level determination in schizophrenia patients

被引:26
作者
Aravagiri, Manickam [1 ]
Marder, Stephen R.
Pollock, Bruce
机构
[1] Univ Calif Los Angeles, Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA
[2] Univ Pittsburgh, Geriatr Psychopharmacol Program, Pittsburgh, PA 15260 USA
[3] Univ Toronto, Rotman Res Inst, Toronto, ON M4X 1K9, Canada
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2007年 / 847卷 / 02期
关键词
ziprasidone; LC-MS-MS; schizophrenia patients; plasma analysis; ziprasidone levels;
D O I
10.1016/j.jchromb.2006.10.024
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
An accurate, rapid and simple liquid chromatography-tandem mass spectrometry (LC-MS-MS) assay method was developed for the determination of ziprasidone (ZIP) in the plasma of schizophrenia patients. A simple one step liquid-liquid extraction with 20% methylene dichloride in pentane was used to isolate ZIP and the internal standard from the plasma matrix. The compounds were separated on a C-18 column by an isocratic elution and the eluted compounds were analyzed by a triple quadrupole mass spectrometer with a Turbolon spray interface using the positive ion atmospheric pressure electrospray ionization method and detected using multiple reaction monitoring mode. The ZIP standard calibration curve was linear over the range of 0.25-500 ng/ml when 0.5 ml of plasma was used for the analysis (r(2) > 0.998). The intra-assay (within-day) and inter-assay (between-day) variations were less than 12% for the spiked standard curve and quality control samples. The absolute extraction efficiency was 82% for ZIP and 68% for INS-RSP. The analysis time for each sample was less than 3 min and useful for high turnaround plasma level determinations. This LC-MS-MS assay method for ZIP is highly specific, sensitive, accurate and rapid and is currently being used for the plasma level determination of ZIP in schizophrenia patients treated with various daily oral doses of ZIP. The data showed large inter-individual variations. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:237 / 244
页数:8
相关论文
共 21 条
  • [1] Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation
    Cohen, S
    Fitzgerald, B
    Okos, A
    Khan, S
    Khan, A
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (01) : 60 - 62
  • [2] Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies
    Correll, CU
    Leucht, S
    Kane, JM
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (03) : 414 - 425
  • [3] DIRBASHI OY, 2006, BIOMED CHROMATOGR, V20, P365
  • [4] Stability indicating reversed-phase high-performance liquid chromatographic and thin layer densitometric methods for the determination of ziprasidone in bulk powder and in pharmaceutical formulations
    El-Sherif, ZA
    El-Zeany, B
    El-Houssini, OM
    Rashed, MS
    Aboul-Enein, HY
    [J]. BIOMEDICAL CHROMATOGRAPHY, 2004, 18 (03) : 143 - 149
  • [5] Janiszewski J, 1997, RAPID COMMUN MASS SP, V11, P1033
  • [6] DEVELOPMENT AND VALIDATION OF A HIGH-SENSITIVITY ASSAY FOR AN ANTIPSYCHOTIC AGENT, CP-88,059, WITH SOLID-PHASE EXTRACTION AND NARROW-BORE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
    JANISZEWSKI, JS
    FOUDA, HG
    COLE, RO
    [J]. JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 668 (01): : 133 - 139
  • [7] Ziprasidone and weight gain
    Jaworowski, S
    Hauser, S
    Mergui, J
    Hirsch, H
    [J]. CLINICAL NEUROPHARMACOLOGY, 2004, 27 (02) : 99 - 100
  • [8] A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone
    Mamo, D
    Kapur, S
    Shammi, CM
    Papatheodorou, G
    Mann, S
    Therrien, FO
    Remington, G
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (05) : 818 - 825
  • [9] MICELI JJ, 2000, BR J CLIN PHARM, V49, P5
  • [10] NARSALLAH H, 2003, PSYCHONEUROEDOCRI S1, V28, P83